Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 201.80 |
| Open | 202.53 |
| Bid | 200.74 x 300 |
| Ask | 209.05 x 100 |
| Day's range | 198.55 - 203.24 |
| 52-week range | 189.44 - 269.43 |
| Volume | |
| Avg. volume | 989,153 |
| Market cap | 29.25B |
| Beta (5Y monthly) | -0.06 |
| PE ratio (TTM) | 25.32 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
- Investor's Business Daily
Is Eli Lilly Stock A Buy After Slashing The Price Of Its New Weight-Loss Drug?
Eli Lilly halved the price of a new version of its weight-loss drug, Zepbound. Is Eli Lilly stock a buy right now?
© 2024 Yahoo. All rights reserved.